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Alpha-1 antitrypsin deﬁciency is a monogenic disorder result-
ing in emphysema due principally to the unopposed effects of
neutrophil elastase. We previously reported achieving plasma
wild-type alpha-1 antitrypsin concentrations at 2.5%–3.8% of
the purported therapeutic level at 1 year after a single intramus-
cular administration of recombinant adeno-associated virus
serotype 1 alpha-1 antitrypsin vector in alpha-1 antitrypsin
deﬁcient patients. We analyzed blood and muscle for alpha-1
antitrypsin expression and immune cell response. We also as-
sayed previously reported markers of neutrophil function
known to be altered in alpha-1 antitrypsin deﬁcient patients.
Here, we report sustained expression at 2.0%–2.5% of the target
level from years 1–5 in these same patients without any addi-
tional recombinant adeno-associated virus serotype-1 alpha-1
antitrypsin vector administration. In addition, we observed
partial correction of disease-associated neutrophil defects,
including neutrophil elastase inhibition, markers of degranula-
tion, and membrane-bound anti-neutrophil antibodies. There
was also evidence of an active T regulatory cell response
(similar to the 1 year data) and an exhausted cytotoxic T cell
response to adeno-associated virus serotype-1 capsid. These
ﬁndings suggest that muscle-based alpha-1 antitrypsin gene
replacement is tolerogenic and that stable levels of M-AAT
may exert beneﬁcial neutrophil effects at lower concentrations
than previously anticipated.
INTRODUCTION
Alpha-1 antitrypsin (AAT) deﬁciency is among the most prevalent
monogenic disorders worldwide, with an estimated 181,000 individ-
uals possessing the most common genotype associated with severe
disease (homozygous E342K or PI*ZZ).1 The common mutation
leads to impaired secretion of AAT from its primary site of synthesis,
the hepatocyte. The two primary diseases associated with AAT muta-
tion are lung disease, due to a deﬁciency of AAT protein in circula-
tion, and liver disease, which is due to the downstream consequences
of the aggregation and polymerization of the mutant Z-AAT protein
in hepatocytes.
The onset of respiratory disease in patients with AAT deﬁciency
generally manifests in the fourth and ﬁfth decade of life for smokers
and can be delayed to the sixth decade for non-smokers, while some
non-smoking AAT deﬁcient patients never develop lung disease. The
lung disease is thought to be due to absence or low activity of AAT
and consequently its inability to fully inactivate neutrophil elastase
and other neutrophil-derived proteases.2 Over time, this anti-prote-
ase/protease imbalance leads to degradation of the alveolar walls
and the surrounding connective tissue elastin matrix, which leads
to a decrease in lung elasticity and surface area. The classic descrip-
tion includes panacinar emphysema, with a lower lobe predominance,
but patients often manifest other symptoms, including cough and
wheezing, which may relate to both an increase in airway inﬂamma-
tion and a decrease in airway tethering as a consequence of the loss of
interstitial elastin.3 Current therapy for AAT lung disease consists of
weekly intravenous infusions of wild-type (M) AAT protein, along
with supportive and compensatory therapies, such as antibiotics,
oxygen supplementation, and lung transplantation for end-stage pul-
monary disease.
Clinical gene augmentation therapy for AAT lung disease has been
developed using recombinant viral or non-viral vectors that express
M-AAT.4–17 Cationic liposome delivery of AAT plasmid DNA to
the respiratory epithelium was attempted to explore feasibility.4–8
Intrapleural administration of rAAV-rh10-AAT has been explored
more recently and is entering early phase trials.12 Meanwhile,
rAAV2-AAT and rAAV1-AAT vectors have been developed for
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intramuscular (IM) administration by our group.13–16,18,19 The
rAAV1-AAT vector has been used in a phase 1 trial of IM adminis-
tration in AAT deﬁcient adults and has demonstrated dose-depen-
dent, sustained expression of M-AAT in the absence of signiﬁcant
adverse effects.13,16,18,19
A phase 2a trial of direct IM injection of rAAV1-CB-hAAT was
undertaken in nine adult patients with severe AAT deﬁciency, at
doses ranging from 6.0  1011 vg/kg to 6.0  1012 vg/kg, in order
to evaluate safety and to determine whether the dose response to
vector would be linear within this range. The 3-month results of
that trial indicated that vector administration was safe and that a
linear dose-related increase in serum M-speciﬁc AAT levels was
observed.13 Interestingly, the vector used in this trial was produced
using an HSV1-based helper system, as compared with a transfec-
tion-based system in the phase 1 trial, and the phase 2a trial
conﬁrmed an increased bioactivity of vector on a vg/kg basis.
Longer-term follow up of the subjects in this trial at 12–18 months
after vector administration demonstrated that vector expression
persisted at high levels despite an ongoing AAV1-capsid speciﬁc
ELISPOT response in peripheral blood, and this persistence was
linked to the presence of capsid-speciﬁc regulatory T cells (Tregs)
in the muscle and the peripheral blood and to PD-1 expression in
the muscle.18 The current report extends these ﬁndings with an
approximately 5 year follow up of vector expression, anti-protease
biomarkers, and immune proﬁles. We primarily focused on one pa-
tient (#308) from the original study who has not been treated with
AAT protein replacement therapy. These studies demonstrated
continued stable transgene expression at 5 years after administra-
tion and examined the effects of sustained M-AAT protein expres-
sion on neutrophil defects that have been associated with the AAT
deﬁciency state and immunologic parameters in blood and muscle.
In addition, we demonstrate two of the three patients in the high
dose group also have increased serum anti-elastase activity after
gene therapy.
RESULTS
Stable Transgene Expression from Muscle
In order to determine the stability of transgene expression after
one-time IM administration of rAAV1-hAAT, serum M-AAT
levels were determined at yearly intervals from subjects in a
previously published phase 2a trial who were not receiving
AAT augmentation therapy. Subject 308, in the high dose
cohort, had stable transgene expression at a level greater than
2% of the accepted therapeutic target of 11 mM (Figure 1) as deter-
mined by a previously published M-AAT speciﬁc ELISA.16 A mus-
cle biopsy from this patient, performed at 5 years after vector
dosing, also showed ongoing transgene expression, as indicated
by substantial AAT immunoreactivity within the sarcoplasm
of myoﬁbers (Figure 2). Myoﬁbers varied substantially in the in-
tensity of AAT staining, with scattered high-expressing ﬁbers
interspersed among ﬁbers with little or no detectable reactivity.
A summary of the hAAT immunohistochemistry results are pro-
vided in Table 1.
Histological Features of the Injection Site
The histological features of muscle at the injection site were exam-
ined by hematoxylin-eosin staining and semiquantitative immuno-
phenotyping (Figure 3). The overall proﬁle of cellular inﬁltrates is
described in Table 2. Immunohistochemical staining indicated
rare “microfoci” of CD3+ inﬂammatory inﬁltrates. CD3-immunore-
active T-lymphocytes comprised the most abundant single subset of
mononuclear cells, with CD8+ cells accounting for slightly more
of the total inﬂammatory cell population than CD4-reactive cells.
Scattered CD20+ B-lymphocytes and CD68+ macrophages were
also seen. However, when compared with the results reported
from the 3- and 12-month biopsies from the same patient, the
abundance of inﬁltrating lymphocytes of all types appears to have
decreased. Bisulﬁte sequencing was used to quantitatively charac-
terize the immunophenotyping results and examine the unique
methylation status of the activated FoxP3 promoter (indicative
of FoxP3+ Treg cells), as well as the methylations signature of
the activated CD8 locus associated with CD8-expressing cells
(Figure 4). The absolute sequencing counts for both the CD8+
and Tregs decreases over time as was observed in the histological
evaluation. However, as reported at the 12-month time point,18 a
relatively high proportion of Tregs is observed and maintained
over time.
Characterization of T Cells from the Injected Muscle
In order to study in situ inﬁltrating lymphocytes more thoroughly,
cells were extracted from the muscle biopsy tissue using previously
published methods and analyzed by ﬂow cytometry (Figure 5).20
These analyses conﬁrmed the bisulﬁte sequencing data and also
Figure 1. M-AAT Serum Levels over the 5 Years after Intramuscular
Administration of rAAV1-CB-hAAT
The dotted line is at 2.5% of the target therapeutic serum concentration of
572 mg/mL (11 mM). The serum AAT levels were assayed using a M-AAT-specific
ELISA. The high dose was 6.0  1012 vg/kg, the mid dose was 1.9  1012 vg/kg,
and the low dose was 6.0  1011 vg/kg. Early time points previously reported in
Mueller et al.18
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showed the presence of Tregs among CD3
+CD4+ muscle-inﬁltrating
lymphocytes (MIL), with greater than 6% of CD4+ cells demon-
strating the Helios+FoxP3+ Treg phenotype. Further analysis of the
status of the muscle inﬁltrating Tregs revealed that more than 75%
of the cells were activated as assessed by the upregulation of both
CD25 and OX-40. In contrast to the MIL Treg population, which
was characterized by general activated status, about 10% of the
CD8+ MIL population was expressing high levels of PD-1 and
LAG-3, consistent with T cell exhaustion.
Characterization of Peripheral Blood T Cell Responses to AAV1
Capsid Epitopes
Speciﬁc peripheral blood T cell responses to AAV1 capsid epitopes
were examined using a gamma-interferon ELISPOT assay. Peripheral
blood reactivity to AAV1 epitopes, when compared with that
observed at earlier time points, had decreased in magnitude,
Figure 2. M-AAT Expression in Skeletal Muscle 3
Months, 12 Months, and 5 Years after Intramuscular
Administration of rAAV1-CB-hAAT
Muscle immunochemistry staining for hAAT. The speci-
mens were biopsied from the area injected with rAAV1
and the tissue stained for hAAT (brown). The AAT
expression was persistent, while inflammatory cell in-
filtrates decreased over time from 3 months to 5 years. All
of the slides are from patient 308. (A) Tissue 3 months
after rAAV1-CB-hAAT delivery. (B) Tissue 12 months after
rAAV1-CB-hAAT delivery. (C and D) Tissue 5 years after
rAAV1-CB-hAAT delivery.
Table 1. Summary of hAAT Immunohistochemistry Results at the Indicated
Time Points in Muscle Biopsies from Subject 308
Time Point 308 3 Months 308 12 Months 308 5 Years
Sample number 1 2 1 2 1
Myoﬁbers 1+ 1+ NE 1+ 1+
Endomysium 1+ 1+ NE 1+ 1+
Intravascular 3+ 3+ NE 3+ 3+
Vascular endothelium NE NE NE 3+ 2+
Scoring indicates positive hAAT staining in different regions of the muscle sample.
hAAT expression was maintained through the 5 year time point. The scoring scale is
as follows: 0 (absent, none), 1+ (occasional, focal, mild, scattered, and slight), 2+ (prom-
inent, marked, andmoderate), or 3+ (strong, extensive, and severe). NE = not examined.
but remained signiﬁcantly above background
within epitope pools AAV1b and AAV1c at
52 months after injection (Figure 6).
Biomarkers of Biological Activity of
Transgene-Expressed AAT
The augmentation of PiZ homozygous individ-
uals with stable levels of M-AAT between 2%
and 3% of the therapeutic threshold has never
been studied with protein replacement or by any other means.
The following observations therefore constitute the ﬁrst description
of the functional effect of augmenting M-AAT below the canonical
therapeutic threshold of 11 mM (572 mg/mL). The most direct func-
tional assay for AAT bioactivity is to quantify its ability to inactivate
neutrophil elastase (NE). Given that secreted AAT from AAV trans-
duced muscle reaches steady-state levels in serum, we analyzed the
ability of the patients’ sera to inactivate human elastase otherwise
known as the sera’s anti-neutrophil elastase capacity (ANEC). As
shown in Figure 7, two out of three patients had low ANEC activity
prior to the gene therapy as compared to a cohort of control PiM
individuals. ANEC activity for patient 308 was, however, high and
comparable to that of a PiM (wild-type) patient. This was not ac-
counted for by total AAT or PiZ AAT levels, suggesting that this in-
dividual had an elevated level of another serum anti-protease, which
may have accounted for her high ANEC and her mild clinical
phenotype. At 3 months post-gene delivery, the ANEC activity
was strongly increased in patient 306 and patient 307, which is
highly suggestive of a biological effect in these two subjects; it re-
mained stable in patient 308. At 1 year post intervention, the
ANEC activity remained either comparable to the 3 month values
(patients 306 and 308) or increased further (patient 307). Patients
306 and 307 subsequently started protein augmentation therapy
and their ANEC activity further increased to normal levels at the
5 year time point. Patient 308, who remained off protein augmen-
tation therapy 5 years after gene delivery, maintained stable yet
high ANEC activity.
Surface anti-lactoferrin staining on neutrophils and circulating serum
tumor necrosis factor receptor 1 (TNF-R1) have been recently
demonstrated to respond to augmentation therapy.21 Both these
www.moleculartherapy.org
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markers were found to decrease signiﬁcantly after gene therapy
(Figure 8). Remarkably, two out three patients in high dose
cohort showed approximately %50 correction of the circulating
TNF-R1, suggesting that signiﬁcant biological activity may have
been achieved (Figure 8A). It should be noted that patient 306
did not show a decrease at the 5 year time point. This patient had
Table 2. Summary of Leukocyte Phenotyping Immunohistochemistry
Results at the Indicated Time Points in Muscle Biopsies from
Subject 308
Subject Number 308 3 Months 308 12 Months 308 5 Years
Sample number 1 (%) 2 (%) 1 2 (%) 1 (%)
CD3 2+50 3+70 NE 3+75 1+5
CD4 1+20 2+25 NE 2+30 1+5
CD8 2+30 2+45 NE 2+45 1+5
CD20 1+20 1+15 NE 1+5 1+5
CD68 2+30 1+10 NE 1+20 1+5
Inﬂammatory scores decreased over time following vector injection including an overall
decrease in the percentage of all inﬂammatory cell types. CD3: staining for T-lympho-
cytes. CD4: staining for help T cells. CD8: staining for cytotoxic T cells. CD20: staining
for B-lymphocytes. CD68: staining for macrophages. Phenotype results were scored 1+
(<25%), 2+ (25%–65%), or 3+ (>65%).
Figure 3. Immunophenotyping of Cellular Infiltrates
in Skeletal Muscle at the Injection Site 5 Years after
Intramuscular Administration of rAAV1-CB-hAAT
(A) hAAT immunohistochemistry showing microfoci of
immune cells around cell expression hAAT. (B) CD3
staining, demonstrating that many of the mononuclear
immune cells are T-lymphocytes. (C) CD8 staining indi-
cating a population of cytotoxic T cells. (D) CD68 staining
indicating a population of macrophages. (E) CD20 staining
indicating a small population of B-lymphocytes.
the worst clinical condition of any patient in
the high-dose cohort and required a lung trans-
plant and was subsequently diagnosed with pul-
monary Aspergillosis, prior to collection of the
5 year serum.
DISCUSSION
The multiyear persistence of rAAV expression
in human gene therapy trial participants has
been reported after a number of routes of deliv-
ery, including subretinal, intravenous, and
intramuscular routes. However, this is the ﬁrst
report in which such results were obtained
without immune suppression or corticosteroid
therapy. The fact that this persistence in the
absence of immune suppression coincides with
ongoing evidence of an AAV1-capsid speciﬁc
Treg response and of CD8
+ T cell exhaustion
suggests that these mechanisms may be opera-
tive in this context. It should be noted that in an earlier report
from this trial at the 1 year follow up time point, we could not iden-
tify cells positive for Treg markers in normal control muscle tissue,
further supporting that this ﬁnding is unique to the vector injected
muscle.18 While the Treg percentage in the vector-injected muscle
was approximately 10% of all CD3+ T cells, it should be noted
that biological activity of Treg cells in functional assays is typically
observed at ratios as low as 0.1%.22 What remains unclear is whether
these immunologic ﬁndings are generalizable to intramuscular gene
therapy with rAAV expressing other transgenes and at other doses,
or indeed whether this might be observed with other routes of deliv-
ery. It is also not clear whether the levels observed in the current
study could have been further enhanced with corticosteroid or other
immune suppressive therapy.
The ﬁnding of partial correction of multiple indicators of AAT bio-
logical activity, including elastase inhibition, auto-antibodies, and
the neutrophil degranulation phenotype in AAT deﬁcient patients
is also quite signiﬁcant. The target level of 11 mM (570 mcg/mL)
that has been used as the target for protein and gene replacement
was based on compound heterozygotes with the genotype PI*SZ.
Since neither the S nor the Z variants of AAT have full speciﬁc
activity, it is unknown precisely what level of M-AAT would be
Molecular Therapy
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required to achieve an equivalent biological effect. The IV protein
replacement of M-AAT, which is the current standard of therapy,
is not an ideal surrogate for establishing a target for gene
therapy, because of the drastic peaks and troughs of serum levels
observed after each weekly or bi-weekly infusion. In fact, there is
no clinical precedent for what was achieved in the patients described
here, where approximately 2.5% of the target level was produced
continuously, without any peak and trough effects. Theoretically,
this could exert a greater pharmacodynamic effect, analogous to
the greater beneﬁt afforded by insulin pumps in patients with dia-
betes in prevention of microvascular complications, as compared
with the same total daily insulin dose when administered in split
doses. Thus, the ﬁndings of biological efﬁcacy in this context
could be of major signiﬁcance if they can be conﬁrmed in future
studies and are later found to correlate with clinically meaningful
effects.
Earlier reports from this trial indicated a reproducible dose-
response relationship between the dose of rAAV1-AAT and the
serum levels of M-AAT observed.13 This bodes well for future
studies in which alternative methods of muscle delivery, such as
limb perfusion, might enable a further increase in dose and in the
absolute serum M-AAT level achieved. Other routes of delivery,
such as intravenous or intrapleural, are also being investigated.12
Intravenous delivery, similar to that used in the hemophilia B and
hemophilia A trials, would almost certainly require the use of cor-
ticosteroids or other immune suppressive drugs. There is also a
theoretical concern that overexpressing M-AAT within hepatocytes
of PiZ patients could exacerbate subclinical liver disease in these
patients, most of whom show histologic evidence of a substantial
load of retained mutant within their hepatocytes.23,24 Thus, given
the encouraging ﬁndings regarding the sustained biologic activity
and immunologic tolerance seen with IM delivery, it would seem
worthwhile to continue to pursue the muscle-based platform for
gene replacement of this and possibly other secreted proteins. In
addition to modifying the delivery method for this vector, future
studies could theoretically further enhance the M-AAT expression
by modiﬁcations to the vector capsid, promoter, and through codon
optimization.
MATERIALS AND METHODS
Experimental Design
As indicated in previous reports, the study was conducted as an
open-label, non-randomized, multicenter, sequential, 3-arm, phase
II clinical trial to evaluate the safety and efﬁcacy of administering
a rAAV1-CB-hAAT vector intramuscularly.13,18 The study was
conducted under an IND with approval of the University of
Massachusetts Medical School and Cincinnati Children’s Hospital
institutional review boards and institutional biosafety committees
and in accordance with the tenets of the declaration of Helsinki.
This study is registered with Clinical Trials.gov (NCT01054339).
There were nine subjects (three per cohort) that received
intramuscular doses of rAAV1-CB-hAAT (6  1011, 1.9  1012,
or 6  1012 vg/kg body weight). The rest of the study design was
reported earlier.13
Laboratory Assessments, In Situ Staining, and Bisulfite
Sequencing
AAT serum levels and ELISPOTs were done as previously described
in the 3 month interim report.13 Immunohistochemical staining to
detect hAAT protein within myoﬁbers as well as to characterize cell
surface markers on inﬁltrating cells was performed as previously re-
ported.18 Bisulﬁte sequencing of immune cells was done as previously
described in the 1 year report.18
Regulatory T Cell and Exhausted T Cell Detection by Flow
Cytometry
The patient muscle biopsy sample was cut into approximately 5 mm3
pieces and incubated in RPMI media supplemented with DNase I
(62.5 U/mL, Zymo Research) and collagenase (0.25 mg/mL, Roche)
for 2 hr at 37C. Cell suspension was homogenized and ﬁltered using
a 70 mm cell strainer before staining. Regulatory T cells and ex-
hausted CD8+ T cell populations were analyzed using CD3/CD4/
Helios/FoxP3/CD25/OX40 and CD3/CD8/PD1/LAG3 markers,
respectively. Extracellular staining consisted of cell incubation on
ice for 30 min. Cells were then washed twice with 1 PBS and resus-
pended in 1 PBS supplemented with 0.5% FBS and 2 mM EDTA.
FoxP3 and Helios intracellular staining was performed according
to manufacturer’s recommendations (anti-human FoxP3 Flow Kit,
Figure 4. Bisulfite Sequencing to Quantify the Percentage of Immune Cells
in Muscle Biopsies Obtained 5 Years after Intramuscular Administration of
rAAV1-CB-hAAT
A relatively high proportion of Tregs was observed in the muscle immune cell
population. (A) Percentage of CD3+, Treg (FOXP3
+), and CD8+ cells in the muscle.
(B) Treg and CD8
+ cells as a percentage of CD3+ cell population in the muscle.
www.moleculartherapy.org
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BioLegend). Cells were acquired using a FACS-LSRII ﬂow cytometer
(BD Bioscience) and analyzed with FlowJo software (version 10.1;
Tree Star).
Neutrophil Elastase Activity
Relative serum neutrophil elastase activity was quantiﬁed by a color-
imetric assay, according to the manufacturer’s instructions (Enzo Life
Figure 5. Regulatory T Cell and Exhausted T Cell Detection by Flow Cytometry in Samples from Muscle Biopsies Obtained 5 Years after Intramuscular
Administration of rAAV1-CB-hAAT
(A) Regulatory T cells were gated asHelios+FoxP3+ cells in the CD3+CD4+ subset. The activated Treg cells were defined as OX40
+CD25+ cells. (B) Exhausted CD8 T cells were
gated as LAG-3+PD-1+ cells in the CD3+CD8+ subset. The percentages of each population are indicated in the dot plots.
Figure 6. Peripheral Gamma-IFN ELISPOT
Responses to AAV Capsid Epitope Pools
A decreased peripheral blood AAV1 reactivity was
observed at month 52 compared to earlier time points (all
of the data from patient 308). SFU, spot forming units;
PBMC, peripheral blood mononuclear cell; AAV1a/b/c,
pools of AAV1 peptides; CEF, positive control peptide
pool.
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Sciences). Brieﬂy, neutrophil elastase was diluted in 37C assay buffer
to 2.2 mU/mL. Elastinal (100 mM) or patient serum was added to each
well followed by a 30 min incubation at 37C to allow inhibitor/elas-
tase interaction. Substrate was subsequently added (100 mM) and
absorbance A450nm was read every minute for 60 min. Data were
analyzed by determining the slope of the kinetic for each sample,
the slopes of the three technical replicates were averaged, values
were reduced by subtracting the slope of the blank (buffer and sub-
strate), and normalized by setting the control (buffer, substrate, and
elastase) at 100%.
Neutrophil Anti-Lactoferrin and TNF-R1 Assay
Fixed and blocked neutrophils (1  106/mL in PBS) were incubated
with Rb anti-lactoferrin primary (2 mg) antibody or isotype control
antibody (Rb IgG) for 2 hr at room temperature.
After two steps of washing in PBS, cells were then incubated with
Gt-anti-rabbit FITC labeled secondary antibody (1 hr at room tem-
perature) and then washed again. Fluorescence was counted using
a BD FACSCalibur ﬂow cytometer (BD Bioscience) with a total of
10,000 events acquired. The data were analyzed using BD CellQuest
Pro software. The TNF-R1 assay was performed as previously
described.21
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